Hospitalisations related to systemic sclerosis and the impact of interstitial lung disease. Analysis of patients hospitalised at the University of Michigan, USA.
Journal
Clinical and experimental rheumatology
ISSN: 0392-856X
Titre abrégé: Clin Exp Rheumatol
Pays: Italy
ID NLM: 8308521
Informations de publication
Date de publication:
Historique:
received:
09
09
2020
accepted:
22
02
2021
pubmed:
19
3
2021
medline:
3
8
2021
entrez:
18
3
2021
Statut:
ppublish
Résumé
To determine the primary reason for hospitalisations in systemic sclerosis (SSc) and impact of underlying interstitial lung disease (ILD) in a tertiary scleroderma centre. A retrospective analysis on a subset of a scleroderma cohort from 2011-2019 was performed to assess causes for hospitalisations and mortality. A chart review was performed to extract demographics, primary reason for hospitalisation and inpatient mortality. Admissions were classified as SSc (if hospitalisation reason was related to primary organ dysfunction) and non-SSc related causes. The mean age of the cohort was 53.1 years, 78% were women, and the mean disease duration was 5.2 years. Among 484 patients, 182 (37.6%) were admitted for a total of 634 admissions. In 382 SSc-related admissions, pulmonary hypertension (12.0%) and gastrointestinal dysmotility (11.0%), were major causes of urgent admissions; management of digital vasculopathy (26.1%) was the major reason for elective admissions. In 252 non-SSc related admissions, infection (respiratory:11.5%, skin and soft tissue: 6.3%) was the major reason for urgent admissions, and elective surgery (21.4%) was the major reason for elective admissions. We found 65% of all patients had underlying ILD and a greater proportion of patients with ILD were hospitalised (122 patients). Overall inpatient mortality was 9.3% and the leading cause for mortality was progressive pulmonary hypertension. Among a large cohort of SSc patients who are followed at a tertiary scleroderma centre, 37.6 % had hospital admissions, while worsening pulmonary hypertension, ILD, cardiac involvement and infectious complications were the major cause of mortality and morbidity.
Identifiants
pubmed: 33734968
pii: 16427
pmc: PMC8324531
mid: NIHMS1709845
doi: 10.55563/clinexprheumatol/9ivp9g
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
43-51Subventions
Organisme : NIAMS NIH HHS
ID : K24 AR063120
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR070470
Pays : United States
Organisme : NIAMS NIH HHS
ID : T32 AR007080
Pays : United States
Références
Ann Rheum Dis. 2010 Oct;69(10):1809-15
pubmed: 20551155
Cureus. 2018 May 14;10(5):e2628
pubmed: 30027020
Am J Respir Crit Care Med. 2020 Mar 15;201(6):650-660
pubmed: 31841044
Rheumatology (Oxford). 2007 Dec;46(12):1808-13
pubmed: 17986481
Arthritis Rheumatol. 2019 Aug;71(8):1339-1349
pubmed: 30762947
Clin Rheumatol. 2013 Mar;32(3):361-7
pubmed: 23224269
Curr Opin Rheumatol. 2019 May;31(3):241-249
pubmed: 30870216
Rheumatology (Oxford). 2018 Sep 1;57(9):1611-1622
pubmed: 29868788
Cochrane Database Syst Rev. 2000;(2):CD000953
pubmed: 10796395
Reumatologia. 2017;55(4):163-168
pubmed: 29056770
Lancet. 2017 Oct 7;390(10103):1685-1699
pubmed: 28413064
Rheumatol Int. 2016 Jan;36(1):73-81
pubmed: 26211000
Curr Opin Rheumatol. 2020 May;32(3):228-237
pubmed: 32205570
J Rheumatol. 2018 Feb;45(2):235-241
pubmed: 29142033
Clin Rheumatol. 2016 Jun;35(6):1631-5
pubmed: 27056049
Arthritis Rheumatol. 2020 Jul;72(7):1049-1058
pubmed: 32134199
Clin Exp Rheumatol. 2019 Jul-Aug;37 Suppl 119(4):3-14
pubmed: 31587697
Semin Arthritis Rheum. 2020 Jun;50(3):473-479
pubmed: 31810742
Int J Rheum Dis. 2020 Feb;23(2):137-139
pubmed: 32043307
Eur Respir J. 2019 Aug 22;54(2):
pubmed: 31196948